Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

13. november 2026 opdateret af: Viking Therapeutics, Inc.

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight

This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.

Studieoversigt

Status

Rekruttering

Betingelser

Detaljeret beskrivelse

This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

560

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Arizona
      • Tucson, Arizona, Forenede Stater, 85741
        • Rekruttering
        • Viking Clinical Site #2020
        • Kontakt:
          • Telefonnummer: 520-333-4515
    • California
      • Lake Forest, California, Forenede Stater, 92630
        • Rekruttering
        • Viking Clinical Site #2015
        • Kontakt:
          • Telefonnummer: 714-550-9990
    • Florida
      • Ocoee, Florida, Forenede Stater, 34761
        • Rekruttering
        • Viking Clinical Site #2059
        • Kontakt:
          • Telefonnummer: 407-654-2724
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30329
        • Rekruttering
        • Viking Clinical Site #2013
        • Kontakt:
          • Telefonnummer: 404-920-6201
    • Indiana
      • Evansville, Indiana, Forenede Stater, 47714
        • Rekruttering
        • Viking Clinical Site #2001
        • Kontakt:
          • Telefonnummer: 812-477-2760
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Rekruttering
        • Viking Clinical Site #2046
        • Kontakt:
          • Telefonnummer: 504-336-2667
      • Valparaiso, Indiana, Forenede Stater, 46383
        • Rekruttering
        • Viking Clinical Site #2009
        • Kontakt:
          • Telefonnummer: 219-464-8302
    • Minnesota
      • Richfield, Minnesota, Forenede Stater, 55423
        • Rekruttering
        • Viking Clinical Site #2004
        • Kontakt:
          • Telefonnummer: 952-922-7000
    • Mississippi
      • Jackson, Mississippi, Forenede Stater, 39206
        • Rekruttering
        • Viking Clinical Site #2029
        • Kontakt:
          • Telefonnummer: 770-330-4157
    • Missouri
      • Springfield, Missouri, Forenede Stater, 65807
        • Rekruttering
        • Viking Clinical Site #2028
        • Kontakt:
          • Telefonnummer: 504-338-0917
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87107
        • Rekruttering
        • Viking Clinical Site #2052
        • Kontakt:
          • Telefonnummer: 505-243-1627
    • New York
      • Binghamton, New York, Forenede Stater, 13905
        • Rekruttering
        • Viking Clinical Site #2039
        • Kontakt:
          • Telefonnummer: 607-800-5777
    • Oregon
      • Medford, Oregon, Forenede Stater, 97504
        • Rekruttering
        • Viking Clinical Site #2023
        • Kontakt:
          • Telefonnummer: 541-858-1018
    • Rhode Island
      • East Greenwich, Rhode Island, Forenede Stater, 02818
        • Rekruttering
        • Viking Clinical Site #2002
        • Kontakt:
          • Telefonnummer: 401-739-9350
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29407
        • Rekruttering
        • Viking Clinical Site #2044
        • Kontakt:
          • Telefonnummer: 843-432-2477
    • Tennessee
      • Hendersonville, Tennessee, Forenede Stater, 37075
        • Rekruttering
        • Viking Clinical Site #2030
        • Kontakt:
          • Telefonnummer: 504-339-0917
    • Texas
      • Abilene, Texas, Forenede Stater, 79606
        • Rekruttering
        • Viking Clinical Site #2031
        • Kontakt:
          • Telefonnummer: 325-400-1150
    • Washington
      • Seattle, Washington, Forenede Stater, 98105
        • Rekruttering
        • Viking Clinical Site #2011
        • Kontakt:
          • Telefonnummer: 206-536-3030
      • Spokane, Washington, Forenede Stater, 99218
        • Rekruttering
        • Viking Clinical Site #2042
        • Kontakt:
          • Telefonnummer: 509-505-6227

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥18 years of age at the time of signing the informed consent.
  2. Body mass index (BMI) ≥ 27 kg/m2
  3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.

Exclusion Criteria:

  1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation

  2. Self-reported body weight change of 5% or more within 3 months of screening

  3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)

  4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)

  5. Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)

  6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening

    • Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL.

  7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization

  8. Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.

  9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)

  10. History of acute or chronic pancreatitis

  11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo Assignment

Placebo comparator orally once daily

Placebo comparator administered orally once daily

Eksperimentel: Active Assignment (Dose 1)

VK2735 Dose level 1 orally once daily

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

Eksperimentel: Active Assignment (Dose 2)

VK2735 Dose level 2 orally once daily

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

Eksperimentel: Active Assignment (Dose 3)

VK2735 Dose level 3 orally once daily

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily
Tidsramme: 68 weeks

To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68

68 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. november 2026

Primær færdiggørelse (Anslået)

1. oktober 2028

Studieafslutning (Anslået)

1. december 2028

Datoer for studieregistrering

Først indsendt

5. oktober 2026

Først indsendt, der opfyldte QC-kriterier

5. oktober 2026

Først opslået (Faktiske)

9. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • VK2735-305

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner